10-Q: BioScience Health Innovations Reports Net Income for Q1 2025, Revenue Surges

BioScience Health Innovations Inc. reports a significant turnaround with net income of $426,798 for Q1 2025, compared to a net loss in the same period last year, driven by increased revenue and strategic initiatives.

Summary

• BioScience Health Innovations Inc. reported a net income of $426,798 for the three months ended March 31, 2025, a significant improvement from the net loss of $53,381 in the same period of 2024.
• Revenue increased substantially to $1,227,070 from $277,601 year-over-year, attributed to company growth and enhanced sales and marketing efforts.
• Operating expenses also increased, with general and administrative expenses rising to $433,561 and consulting fees to $35,786.
• The company's total assets as of March 31, 2025, were $1,394,959, including cash, accounts receivable, inventory, prepaid expenses, and intangible assets.
• The company is pursuing a private placement to raise up to $1,000,000 and plans to file Form 1-A with the SEC.
• Management is optimistic about opportunities in the mental health and general wellness markets, particularly with patent-pending Methylene Blue products.
• The company is developing a proprietary liquid mineral solution for oral delivery of GLP-1 receptor agonists, aiming for regulatory compliance and patient preference.
• The company is evaluating a reverse stock split (4:1) to streamline share structure for Nasdaq compliance.
• The company acknowledges material weaknesses in internal control over financial reporting and plans to rectify them by establishing written policies and procedures and hiring additional accounting personnel.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with significant revenue growth and a shift to profitability. However, concerns about internal controls and going concern status temper the overall sentiment.

Positives

• The company achieved net income of $426,798 in Q1 2025, a significant turnaround from the net loss in the previous year.
• Revenue increased substantially, indicating strong growth and market traction.
• The development of a patent-pending oral delivery system for GLP-1 receptor agonists presents a significant market opportunity.
• The company's focus on mitochondrial health and related products aligns with growing market interest.
• The company is actively pursuing strategic partnerships to expand its market reach and validate its products.
• The company has generated positive cash flows from operating activities.

Negatives

• The company acknowledges material weaknesses in internal control over financial reporting.
• The company relies on related party transactions, which could raise conflict of interest concerns.
• The company's auditor has expressed doubt about its ability to continue as a going concern.
• The company's supply chain runs through Ageless Holdings LLC, owned by the CEO, which could create potential conflicts of interest or bottlenecks.
• The company's disclosure controls and procedures were ineffective as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is dependent on raising additional funds.
• The company faces risks related to regulatory compliance, particularly with the FDA and FTC.
• The company's reliance on related party transactions could pose financial and operational risks.
• The company's internal control weaknesses could lead to financial reporting errors.
• The company faces potential supply chain disruptions or increased costs due to tariff uncertainty.
• The company has not implemented any specific policies with respect to monitoring and managing cybersecurity threats.

Future Outlook

The company plans to focus on gaining traction for its mental health and general wellness products, particularly those related to mitochondrial health and GLP-1 delivery. Management projects year-over-year revenue growth of 35-50% through 2030.

Management Comments

• As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings.
• We believe mitochondrial health represents the most effective form of preventive medicine, focusing on cellular energy repair and optimization.
• By merging mitochondrial science with an innovative liquid mineral oral GLP-1 delivery mechanism, BioScience Health Innovations is positioned as a disruptive force in the marketplace.

Industry Context

The company is targeting the growing markets for mental health, mitochondrial health, and GLP-1 therapies. The company's focus on natural substitutes and innovative delivery systems positions it to capitalize on these trends.

Comparison to Industry Standards

• The company's gross margins of 60%+ via DTC/Amazon/Wholesale blended averages are competitive within the health and wellness industry.
• The company's focus on patent-pending technologies aims to create a competitive advantage and market exclusivity.
• The company's strategic partnerships with DaVinci Medical/10X Health and The Wellness Company (TWC) leverage established audiences and protocols to enhance mitochondrial health education and outreach.

Related Party Transactions

• During the three months ended March 31, 2025 the Company purchased $456,556 worth of inventory from Ageless Holdings, LLC (Holdings), entity owned and controlled by the Company's members of management and board of directors.
• Additionally, the Company received $589,516 worth of advances from Holdings to pay for operating expenses (inclusive of amounts owed for inventory sales) and the Company paid back $522,000 of the advances.

Stakeholder Impact

• Shareholders: Potential for increased value due to improved financial performance and strategic initiatives.
• Employees: Potential for growth and stability due to company expansion.
• Customers: Access to innovative health and wellness products.
• Suppliers: Increased demand for products and services.
• Creditors: Improved creditworthiness due to stronger financial position.

Next Steps

• Complete the private placement offering to raise up to $1,000,000.
• Prepare and file Form 1-A with the SEC.
• Focus on gaining traction for mental health and general wellness products.
• Commercialize the oral delivery system for GLP-1 receptor agonists.
• Pursue FDA approval via the 505(b)(2) pathway.
• Strengthen leadership by adding two independent directors prior to the planned Nasdaq uplist.

Key Dates

Keywords

Methylene Blue, GLP-1, Mitochondrial Health, Mental Health, Wellness, Revenue, Net Income, Patents, FDA, Nasdaq